Investment companies BBK and Ekarpen led a $16m funding round in Oncomatryx, a biotechnology company, with participation from Kutxabank and the Basque Government. The funds from the capital increase, together with Oncomatryx's recurring income from its license agreements with large international biopharmaceutical companies, will also be used for the clinical development of new drugs from the Oncomatryx pipeline against the tumor microenvironment.